Novartis’ candidate chimeric antigen receptor T (CAR T) cell therapy for cancer is scheduled to be reviewed on 12 July by the US Food and Drug Administration’s Oncologic Drugs Advisory Committee, according to Oxford BioMedica Plc, which is supplying lentiviral vector for the product.
